Among the radionuclide therapy alternatives available in nuclear medicine, several options are reserved for the management of prostate cancer bone metastases, as is the case for 223Ra and, non-specific for bone metastases, [177Lu]Lu-PSMA-617. Here, FOLH1 is linked to prostate carcinoma.